The following table outlines the goodwill balance allocation into the applicable groups of CGUs:


	Americas		Europe		ASPA		MEAI		Total
September 30, 2024		579,864		743,157		165,235		66,365		1,554,621
September 30, 2023		612,814		742,915		167,453		70,735		1,593,917

For each of the fiscal periods, the Company completed its annual impairment test and concluded that there was no impairment during the periods presented.

For purposes of impairment testing the carrying amounts of the groups of CGUs have been compared to their respective value in use as of September 30, 2024 and September 30, 2023.

For all impairment tests, the value in use was determined using a discounted cash flow model. The following key assumptions have been used:


	September 30, 2024
	Americas			Europe			ASPA			MEAI
Terminal Growth Rate		1.5	%		1.5	%		1.5	%		1.5	%
Avg. EBITDA Margin rate (2025-2029)		31.2	%		34.8	%		31.7	%		23.2	%
Pre-tax discount rate		13.9	%		12.9	%		19.6	%		19.6	%
Avg. Revenue growth rate (2025-2029)		15.0	%		16.0	%		30.0	%		30.0	%
Avg. CapEx investments (2025-2029)		41,868			33,296			9,605			5,097


	September 30, 2023
	Americas			Europe			ASPA			MEAI
Terminal Growth Rate		1.5	%		1.5	%		1.5	%		1.5	%
Avg. EBITDA Margin rate (2024-2028)		33.7	%		28.9	%		27.1	%		27.1	%
Pre-tax discount rate		15.3	%		14.7	%		21.4	%		22.2	%
Avg. Revenue growth rate (2024-2028)		15.4	%		17.0	%		30.4	%		30.1	%
Avg. CapEx investments (2024-2028)		44,526			35,361			9,333			4,965

The discount rate is based on a risk-free rate, an equity risk premium adjusted for betas of comparable publicly traded companies, a market risk premium, a country risk premium, and a cost of debt based on comparable corporate bond yields and the capital structure of the Company’s peer group.

As of the years ended September 30, 2024 and 2023, the excess of value in use over carrying amount was sufficient to conclude there were no reasonably likely changes in the assumptions used that would lead to an impairment in any of the CGU groups.